1 / 42

Clinical Trials of Medicines in Ukraine

Clinical Trials of Medicines in Ukraine. Public Enterprise “The State Expert Center of the Ministry of Health of Ukraine” Valentina Nikolaieva PhD, Director of the Board of Preclinical and Clinical Trials. Ukraine. Gained its independence in 1991

karan
Télécharger la présentation

Clinical Trials of Medicines in Ukraine

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Clinical Trials of Medicines in Ukraine Public Enterprise “The State Expert Center of the Ministry of Health of Ukraine” Valentina Nikolaieva PhD, Director of the Board of Preclinical and Clinical Trials

  2. Ukraine • Gained its independence in 1991 • Situated in the central part of Eastern Europe • Capital – Kyiv (about 4 million) • 27 regions • Population – about 45 million • State language - Ukrainian • Precise legislation: Constitution, Laws, Regulations, Orders • More then 1 500 Trial Sites with experience in CT

  3. The rules governing clinical trials (CTs) in Ukraine • Law of Ukraine “On Medicines” • Adopted in 1996 • Articles 7 and 8 regulate conducting of clinical trials Art. 7 « Clinical trial of medicinal products» Clinical trials (CT) are conducted out: - at health care settings (HCSs); - if the positive results of the expert evaluation and assessment of the Ethics Committees at HCS are available; - MoH establishes procedure for conducting expert evaluation; - Ethics Committee (EC) are created and operate at HCSs; - decision to approve aCT protocol is accepted by central executive body for health or its authorized body

  4. The rules governing clinical trials (CTs) in Ukraine • Orders of Ministry of Health of Ukraine which take into account requirements of: • Council Directives 2001/20/EC, 2005/28 EC • ICH GCP • Declaration of Helsinki • WHO recommendations

  5. Order of MoH Ukraine # 690 from 23.09.2009 in the wording of Order of MoH Ukraine # 523 from 12.07.2012 (Registered at the Ministry of Justice of Ukraine on 20.07.2012 under № 1235/21547 and № 1236/21548) Procedure for Conducting Clinical Trials of Medicinal Products and Expert Evaluation of Materials Pertinent toClinical Trials and Model Regulations of the Ethics Committees Regulations of CTs

  6. Regulations of CTs CPMP/ICH/135/95 (E 6) “Note for Guidance on Good Clinical Practice” Order of MoH Ukraine # 95from 16.02.2009: Guidance “Medicinal Products. Good Clinical Practice ССТ-НМОЗУ 42-7.0:2008”

  7. Regulations of CTs CPMP/EWP/QWP/1401/98“Guideline on the Investigation ofBioequivalence” Order of MoH Ukraine # 191from 25.04.2005: Clinical Trials Guidance 42-7.1:2005 “Medicinal Products. Investigations of Bioavailability and Bioequivalence” Directive 2004/10/ЕС Order of MoH Ukraine # 95from 16.02.2009 Guidance “Medicinal Products. Good Laboratory practice”

  8. Regulations of CTs • «Guideline on similar biological medicinal products» (CHMP/437/04/), • «Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues» (EMEA/CHMP/BMWP/42832/2005), • «Guideline on non-clinical and clinical development of similar biological medicinal products containing: • low-molecular-weight-heparins EMEA/CHMP/BMWP/118264/2007) • recombinant erythropoietins (Revision) (EMEA/CHMP/BMWP/301636/2008) • recombinant human soluble insulin (EMEA/CHMP/BMWP/32775/2005) • somatropin (EMEA/CHMP/BMWP/94528/2005) • containing recombinant interferon alfa (EMEA/CHMP/BMWP/102046/2006) • containing recombinant granulocyte-colony stimulating factor (EMEA/CHMP/BMWP/31329/2005)». Methodological recommendations (99.12/190.12.): The general principles ofnon-clinical and clinical issues on similar biological medicinal products containing biotechnology-derived proteins as active substance

  9. Regulations of CTs State Expert Centre of the Ministry of Health of Ukraine (SEC)has been authorized to regulate CTs • Main tasks of SEC: • Expertise of materials of CTs • Approval CTs • Control of CTs (Clinical audit / inspections) • Monitoring SUSAR • Control of compliance of scientific research to the principles of biological and medical ethics

  10. PROCEDURE for Conducting CT of MPand Expert Evaluation of Materials of CT 14 chapters: • General • Definition of terms • General principles of conducting clinical trials • Main requirements to protection of subjects • Requirements to investigators and HCS/clinical trial site • The main requirements to labeling of investigational medicinal product • Obtaining conclusion about expert evaluation of materials concerning a clinical trial of medicinal product (-s) • Assessment of ethical, moral, and legal aspects of the clinical trial • Conducting a clinical trial • Changes and additions during clinical trial • Termination of clinical trial • Notification of adverse events and reactions • Clinical audit of clinical trials of medicinal products • Suspension or full stoppage of a clinical trial

  11. PROCEDURE for Conducting CT of MPand Expert Evaluation of Materials of CT 15 annexes: • LIST OF MAIN DOCUMENTS PERTINENT TO CT • COVER LETTER (CT) • APPLICATION FORM (CT) • COMPLETE DOSSIER OF INVESTIGATIONAL MEDICINAL PRODUCT • APPLICATION OF PRINCIPAL INVESTIGATOR • INFORMATION ABOUT HEALTH CARE SETTING AND CLINICAL TRIAL SITE • NOTIFICATION ABOUT THE START OF CLINICAL TRIAL IN UKRAINE • LIST OF ASPECTS OF CLINICAL TRIAL WHICH MAY BE AMENDED SIGNIFICANTLY BY SPONSOR (LIST OF SIGNIFICANT AMENDMENTS) • COVER LETTER (amendment) • APPLICATION FORM (amendment) • NOTIFICATION ABOUT COMPLETION OF CT • PERIODICAL REPORT ON STATUS OF CT • FORMAT OF FINAL CLINICAL TRIAL REPORT • REQUIREMENTS TO NOTIFICATION ABOUT SUSPECTED UNEXPECTED SERIOUS ADVERSE REACTION • REQUIREMENTS TO STRUCTURE OF UPDATE REPORT ABOUT SAFETY (DSUR)

  12. PROCEDURE for Conducting CT of MPand Expert Evaluation of Materials of CTGeneral principles of clinical trial • CT are conducted according to the ethical principles of the Declaration of Helsinki • CT are conducted at HCS determined by MoH based on the State Expert Center (SEC) positive conclusion • Persons attracted to the performance of clinical trial should have appropriate education, proficiency and experience to perform their functions in CT • Sponsor is entrusted with a choice of investigators • The sponsor may delegate his powers to CRO, but is responsible for initiating CT and the data obtained • Clinical trials shall be commenced when the Center’s positive conclusion approved by MoH, and positive assessment (minutes of the meeting) of the Ethics Committees at HCS are available

  13. PROCEDURE for Conducting CT of MPand Expert Evaluation of Materials of CTGeneral principles of clinical trial • Ensuring confidentiality • CT are planned and conducted in compliance with GCP • If IMP is a narcotic one - compliance with relevant legislation • System of procedures is used to ensure CT quality • Collection, processing and presentation of reliable data • Data storage in HCS at least 15 years • IMPs are produced according to GMP • SEC may conduct clinical audit of CT

  14. Main requirements to conducting CTs • Investigators and the applicant shall be governed by ICH GCP standards • Freely given informed consent should be obtained from every patient or his legal representative prior to participation in a clinical trial

  15. Approvals based on results of an expert evaluation of CT protocol / amendments For conducting CT applicant submit documents are subject to an expert evaluation at the SEC: Application (set form) CT protocol Investigator’s brochure Information for patients and informed consent form Main pages of CRF Insurance contract Certificate of analysis for batch of the IMP ... Approval of CTs by SECApproval of amendments by SECOrder of MoH Ukraine # 523 from 12.07.2012

  16. The main stages of CT approval Applicant Application CT materials Expert evaluation Specialized assessment of CT materials ? Scientific and expert council Protocols – 60 days Amendments – 35 days Approval of CT

  17. Ethical approval of CTs A favorable opinion by Local Ethics Committee is necessary • Obligatory requirement to Ethics Committees - to act according to ICH GCP and Declaration of Helsinki

  18. Quantity of approved CTs per year

  19. International MCTs ( 2008 –2012)

  20. International MCTs 2008 – 2012Specialities (main)

  21. Monitoring of Adverse Reactions during CTs LocalEthicCommittee System of Immediate Reporting SAE immediately According to the Protocol Investigator Sponsor No later 15 days SUSAR (7days – if death) Revealing of serious adverse events (SAEs) SEC Additional information

  22. Monitoring of Adverse Reactions during CTs Periodic Safety Reporting Periodic reports on safety, at least once a year SEC Sponsor Updates of investigator’s brochure

  23. Monitoring of Adverse Reactions during CTs Taking of results into consideration during registration of medicines • Recording of Reports • Collecting of Information • Analyzing of Information SEC Taking appropriate measures regarding CTs 3 CT were stopped due to serious ADRs

  24. Order of MoH Ukraine # 523 from 12.07.2012 Notification of adverse events and reactions(section XII to Procedure) • Notifications to be made by the responsible investigator/ investigator • Notifications to be made by the sponsor • ICH Topic E2A «Clinical Safety Data Management: Definitions and Standards for Expedited Reporting», June 1995 (CPMP/ICH/377/95) • ICH Topic E 6 (R1) Guideline for Good Clinical Practice, July 2002 CPMP/ICH/135/95 • Guidance EC «Communication from the Commission - Detailed guidance on the collection, verification and presentation of adverse event/reaction reports arising from clinical trials on medicinal products for human use, 11 June 2011 (‘CT-3’) (2011/C 172/01)

  25. Order of MoH Ukraine # 523 from 12.07.2012 1. Notifications to be made by the responsible investigator / investigator: 1.1. While conducting clinical trial the responsible investigator/investigator shall report all serious adverse events to the sponsor except for those that the protocol or investigator’s brochure identifies as such not requiring immediate reporting. The initial and follow-up reports shall identify subjects by unique code numbers assigned to them for the study. 1.2. The responsible investigator/investigator shall also report the sponsor any adverse events and/or laboratory abnormalities identified in the clinical trial protocol as critical to safety evaluations according to the requirements and within the time periods specified by the sponsor in the protocol.

  26. continuance Notifications to be made by the responsible investigator / investigator: 1.3. The responsible investigator/investigator shall record immediately and within 7 calendar days after learning about this case all suspected unexpected serious adverse reactions associated with the investigational medicinal product which resulted in death or were life-threatening, to the ethics committee. The follow-up information on this case shall be given to the ethics committee within subsequent 8 calendar days. Requirements to the notification on a suspected unexpected serious adverse reaction are listed in Annex 14 to this Procedure. 1.4. The responsible investigator/investigator shall inform the ethics committee about all other suspected unexpected serious adverse reactions associated with the investigational medicinal product which become known to him within 15 calendar days. 1.5. In case of subject’s death the responsible investigator/investigator shall provide to the sponsor, the Center and the ethics committee any additional information requested by them.

  27. Order of MoH Ukraine # 523 from 12.07.2012 2. Notifications to be made by the sponsor: 2.1.Reporting the suspected unexpected serious adverse reactions to the Center (reporting period) begins from the date of approval by CEBHC of the Center’s conclusion on clinical trial and terminates with the end of clinical trial in Ukraine. 2.2. The sponsor shall record immediately and within 7 calendar days after learning about such case report all suspected unexpected serious adverse reactions associated with the investigational medicinal product which resulted in death or were life-threatening to the Center. Relevant follow-up information on this case shall be given to the Center within subsequent 8 calendar days. Requirements to the notification on a suspected unexpected serious adverse reaction are listed in Annex 14 to this Procedure. 2.3. The sponsor shall report to the Center all other serious unexpected adverse reactions associated with the investigational medicinal product which become known to him within 15 calendar days. 2.4. The sponsor shall inform all responsible investigators/investigators who take part in the clinical trial of this investigational medicinal product concerned on all detected events capable of affecting subjects' safety.

  28. continuance Notifications to be made by the sponsor: 2.5. The sponsor shall keep documentation related to all adverse events the responsible investigators/investigators report to him. 2.6. During long-term clinical trials the sponsor shall provide the Center a written report on the safety of the investigational medicinal product under development in paper and electronic format at least once a year, within 60 calendar days after preparation of the report according to the requirements stated in Annex 15 to this Procedure. In case of the substantiated suspicion on the increased risk for the subjects the Center may oblige the sponsor to submit safety report on the investigational medicinal product under development more frequently. 2.7. In case of conducting several clinical trials of the same investigational medicinal product, the sponsor shall provide to the Center a single generalized report on the safety of investigational medicinal product. In a cover letter attached to the report the sponsor shall provide a listing of all clinical trials conducted in Ukraine or with Ukraine’s participation which are associated with this report. In this case the term of annual reporting begins from the date of receipt of the Center’s conclusion on the conduct of the first listed clinical trial.

  29. Order of MoH Ukraine # 523 from 12.07.2012 REQUIREMENTS TO DEVELOPMENT SAFETY UPDATE REPORT ABOUT INVESTIGATIONAL MEDICINAL PRODUCT (Hereinafter-DSUR)(Annex 15 to Procedure) ICH guideline E2F «Development Safety Update Report», September 2010 (EMA/CHMP/ICH/309348/2008 Committee for medicinal products for human use (CHMP)

  30. Order of MoH Ukraine # 523 from 12.07.2012 DSUR shall consist of 20 sections: 1.Introduction. 2.Worldwide authorization/registration status. 3.Actions taken in the reporting period for safety reasons. 4.Changes to reference safety information. 5.Inventory of clinical trials ongoing and completed during the reporting period. 6.Estimated cumulative exposure (overall effect): 6.1.Cumulative exposure in the development program. 6.2.Patient exposure (patient effect) from marketing experience. 7.Data in line listings and summary tabulations: 7.1.Reference information. 7.2.Line listings of serious adverse reactions during the reporting period. 7.3.Cumulative/summary tabulations of serious adverse events.

  31. continuance of Annex 15 12.Non-clinical data. 13.Literature. 14.Other DSURs. 15.Lack of efficacy. 16.Region-specific information. 17.Late-breaking information. 18.Overall safety assessment: 18.1.Evaluation of the risks. 18.2.Benefit/risk considerations. 19.Summary of important risks. 20.Conclusions. 8.Significant findings from clinical trials during the reporting period: 8.1.Completed clinical trials. 8.2.Ongoing clinical trials. 8.3.Long-term control (follow-up). 8.4.Other therapeutic use of investigational medicinal product. 8.5.New safety data related to the combination therapies. 9.Safety findings from non-interventional studies. 10.Other clinical trial safety information. 11.Safety findings from marketing experience.

  32. SUSAR reports originating worldwide in clinical trials according to protocols approved or not approved in Ukraine and obtained by the Center

  33. SUSAR reports originating in Ukraine and received by the Center

  34. Inspections of Clinical trials(Clinical audit) • Standard Operating Procedures • Inspections cover all CTs including domestic and international CTs • Inspectors – specialists of SEC

  35. Order of MoH Ukraine # 523 from 12.07.2012 Main stages of inspection check-ups Section XIII to Procedure 2001/20/EC 2005/28/EC • Preparing the plan • Notification of sponsor and investigators • Conducting inspection • Investigator • Sponsor Positive conclusion Final inspection report (Act) Detailed inspection report Negative conclusion Critical remarks Essential remarks Non-essential remarks CT Stopped SEC data bank

  36. Inspections of Clinical Trials Performance • Routing check-up during CT conducting • Retrospective check-up after fulfillment CT based on archive data • Targeted check-up review of specific issues • 8 CT were stopped due to • serious ADRs • Critical Violation

  37. Import of registered and unregistered medicines, samples of placebo, related materials/export of biological samples Order of the Ministry of Health of Ukraine of 26.04.2011 №237 “On Approval of the Procedure for the Import of Unregistered Medicinal Products, Certified Reference Materials, and Reagents to the territory of Ukraine” — samples of substances for researches forconducting pre-clinical study; — investigational medicines, reference preparations,samples of placebo forclinical trials and research; — samples of medicines in pharmaceutical forms for registration; — finished medicines for exhibits at exhibitions,conferences, etc. without the right to sell; — finished medicines for individual use by citizens; — in cases of natural disasters, accidents, etc.; — import to the territory of Ukraine of reference medicines and/or substances, contaminants, biological standardpreparations (substances comparison), the referencespectra and reagents for laboratory studies of drugquality.

  38. Quantity of confirmation letters per year

  39. Quantity of confirmation letters per year

  40. Issues in clinical trials - This approach is contrary to the European regulatory practice and recommendations of the International Convention on the Simplification and Harmonization of Customs Procedures, which joined Ukraine in 2006 - Factor taxation prevents the development of clinical trials and reduces investment attractiveness of Ukraine The problem of tax Today, according to the Tax Code of Ukraine medicines imported for the purpose of clinical trials are subject to tax at 20% The exemption will increase the level of foreign investment of 1 billion UAH per year to 3 billion UAH per year over the next 2 years to 8 billion UAH a year over the next 4 years

  41. The present stage of CTs in Ukraine • Adopted CTs regulations • Training programs • Publications: • Periodical medical journals and other publications • Guides on clinical trials • Guidelines on specific issues (organization CTs, statistic considerations, certain patient population: oncology, pulmonology, cardiology etc)

  42. Future of CTs in Ukraine Subsequent development of CTs regulations according to international requirements • Training of investigators and specialists in the field of clinical trials organization • Spreading knowledge of GCP through seminars, conferences, publications

More Related